Vertebrate embryos as tools for anti-angiogenic drug screening and function by Beedie, Shaunna et al.
 
 
Vertebrate embryos as tools for anti-angiogenic drug screening and function 
 
 
 
 
Shaunna Beedie1,2, Alexandra J. Diamond1, Lucas Rosa Fraga1, William D. 
Figg2, Neil Vargesson1, * 
 
 
1 School of Medicine, Medical Sciences and Nutrition, Institute of Medical 
Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK. 
 
2 Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center 
for Cancer Research, National Cancer Institute, National Institutes of Health. 
Bethesda. USA. 
 
 
*Corresponding author  
Neil Vargesson:  n.vargesson@abdn.ac.uk;  nvargesson@gmail.com 
 
 
 
 
 
Key words: angiogenesis, chicken, zebrafish, mouse, rat, rabbit, non-human 
primates, thalidomide  
 
 
 
 
 
 
 
 
 
 
 
 
	 2	
Abstract 
The development of new angiogenic inhibitors highlights a need for robust 
screening assays that adequately capture the complexity of vessel formation, 
and allow for the quantitative evaluation of the teratogenicity of new anti-
angiogenic agents. This review discusses the use of screening assays in 
vertebrate embryos, specifically focusing upon chicken and zebrafish embryos, 
for the detection of anti-angiogenic agents. 
 
Introduction and background 
The cardiovascular system is vital for normal embryonic development in utero [1]. 
It is one of the earliest differentiating and functioning organ systems, 
emphasizing its importance to the embryo [2-7]. The primitive vascular system 
develops by vasculogenesis, de novo differentiation and growth of vessels from 
the mesoderm. The major vessels in the embryo form first, the dorsal aortae 
(transporting oxygenated blood from the placenta or yolk sac to the heart) and 
vena cava or vitelline veins (transporting deoxygenated blood back to the heart 
or yolk sac) develop by vasculogenesis. Expansion of the nascent vascular 
network can then occur by angiogenesis, the process of vessel formation from 
the preexisting vasculature. This process also vascularizes newly forming tissues 
and organs including the developing limbs [8]. Angiogenesis itself is composed of 
several physiological processes; endothelial sprouting, intussusceptive 
angiogenesis and arteriogenesis (the recruitment of smooth muscle to the 
vessel). These processes are discussed in more detail in the following section. 
The angiogenic process is not just limited to embryogenesis. Indeed, 
angiogenesis is vital for menstruation, and wound healing and repair, in the adult. 
Additionally, inappropriate angiogenesis is a hallmark of some pathological 
conditions [9]. Tumour progression, for example, is generally dependent on the 
formation of a vascular supply (although recent studies have shown vessel co-
option is an alternative survival method during tumour development) [10, 11]. The 
newly formed vasculature supplies nutrients, removes waste products, and 
enables tumour growth, and the promotion of metastasis [9]. The vasculature is 
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therefore a novel alternative target for the development of new therapeutic 
agents. In vitro angiogenic assays are limited in their ability to predict new 
compound action, while mouse models are not appropriate for high throughput 
screening. Within this review, we discuss the angiogenic process, and how in 
vivo systems can more accurately depict angiogenesis than in vitro assays. The 
benefits, and drawbacks, of using animal systems for investigating normal 
physiological angiogenesis, and the screening and development of new agents is 
explored. We specifically focus on the benefits of small animal systems, and their 
increasing use in drug screening laboratories. In addition, we use the anti-
angiogenic, teratogenic pharmaceutical agent thalidomide, as an example of a 
complex agent that can be successfully evaluated in these model systems. 
 
Angiogenesis in health and disease 
The precursor to developmental angiogenesis is embryonic vasculogenesis. This 
process begins when the angioblasts from within blood islands (clusters of 
angioblasts), are induced to aggregate by vascular endothelial growth factor A 
(VEFGA) and neuropilin-1 (expressed on the arterial epithelium). The culmination 
of this event is the formation of the primitive vascular plexus (Figure 1). VEGF is 
an inducer of angiogenesis, and an essential factor required for endothelial cell 
survival. Intricate VEGF signaling from the endoderm and mesoderm, then 
promotes the conversion of the primitive vascular plexus to a vascular network 
[12]. The vascular network is extensively remodeled, and following this the 
vessels are stabilized by mural cells, including pericytes (Figure 1). This process 
is regulated by platelet-derived growth factor B (PDGFB) and transforming 
growth factor β (TGF- β) signaling. The onset of blood vessel formation is 
controlled by hypoxia inducible factor (HIF). HIF-1 binds to hypoxia response 
elements within the promoters and enhancers of target genes associated with 
angiogenic growth factors and glucose metabolism. These include VEGF (Figure 
2), PDGF-β, transforming growth factor beta (TGF- β), angiopoietin (Ang2), 
inducible nitric oxide synthetase (iNOS), insulin-like growth factor 2 (IGF-2), 
adrenomedullin, epidermal growth factor (EGF), and urokinase-type plasminogen 
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activator [13]. The combination of increased expression of angiogenic and 
regulatory transcription factors leads to increased blood flow and thus increased 
oxygen delivery [9]. The VEGF, and VEGF receptor system, are best 
characterized, and provide a target for many anti-angiogenic therapies [14] 
(Figure 3). As well as being directed by the expression of growth factors, vessels 
themselves express regulatory signaling molecules to non-vascular cells during 
development. The importance of the vasculature in development is therefore two 
fold, in addition to providing oxygen for tissue development, blood vessels 
express cues fundamental for cell fate specification, embryonic patterning, organ 
differentiation and tissue remodeling. The importance of angiogenesis during 
embryonic development has been shown in multiple mouse knock out models, 
where a loss of genes involved in angiogenesis, such as c-Myc [15], are 
terminally fatal [16, 17]. Loss of VEGF [18] or VE-cadherin [19] results in 
abnormal vascular development, while loss of  HIF-1α [20] or neuropilin [21] 
causes perturbed vascular remodeling. 
 
Moreover, vascular malformations, mispatterning or perturbed vascular 
remodeling in the embryo have been associated with skeletal and other 
morphological defects in a number of human disorders. For example, increased 
prevalence of vascular anomalies are seen in individuals with Schimmelpenning 
syndrome, characterised by craniofacial and skeletal abnormalities [22]. Defects 
caused by vascular disruption, the interruption or prevention of development of 
fetal vasculature, can be a result of disrupted or destroyed embryonic structures 
that would otherwise have developed normally. The type of fetal structural 
defects resulting from vascular disruption depend on the areas affected, usually 
those with most sensitive peripheral vasculature [23]. Limb defects, such as 
clubfoot and limb reduction syndromes, are quite often associated with vascular 
disruption or a failure to produce the correct vascular patterns [24]. Cleft palate 
and craniofacial malformations are also reported. 
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During adulthood, angiogenesis remains important for wound healing, tissue and 
organ functions, and the menstrual cycle. Angiogenesis is also essential for 
tumor growth. Recent years have seen an increase in the use of anti-angiogenic 
agents to treat cancerous and non-cancerous conditions, where inappropriate 
angiogenesis causes disease progression; including ophthalmic diseases [25, 
26], Crohns disease [27, 28], as anti-obesity agents [9, 29] and have also shown 
promise in endometriosis [30-32]. An increased incidence in prescribing drugs to 
treat these conditions requires a thorough understanding of the effects of these 
drugs on the vasculature (Figure 3), as well as possibly the introduction of 
pregnancy prevention programs, for example, the Risk Evaluation and Mitigation 
Strategy (REMS) program used with the prescription of the teratogenic agents 
thalidomide, lenalidomide, and pomalidomide [33]. The REMS program is a 
regulated distribution program, which aims to reduce the risk of embryo-fetal 
exposure to teratogenic compounds, and informs prescribers, pharmacists and 
patients on the serious risks and safe-use conditions for these compounds.  
 
Understanding the mechanisms and/or effects of drugs upon angiogenesis is 
therefore essential to determine effectiveness in treatment of pathological 
conditions like cancer, but also to ensure their use is avoided during pregnancy. 
 
Animal models to study anti-angiogenic drugs and their actions 
To predict the effects or potential of new drugs upon human embryonic health, 
drugs are tested in pregnant animal (usually mammalian) models. Due to their 
rapid development, embryos are highly sensitive to teratogen exposure. 
Laboratory animals can be treated according to specific dosing schedules, and 
their offspring can be assessed for anatomical and physiological abnormalities. 
However, a perplexing aspect of the pharmaceutical agent thalidomide, 
complicates the development of screening assays. Thalidomide, and some other 
drugs (such as valproic acid), exhibits species specificity in its actions [34, 35]; 
for example, thalidomide does not cause congenital abnormalities in certain 
strains of mice [36]. When originally prescribed in the 1950s, thalidomide was 
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presumed to be safe for use during pregnancy. However, it became clear that 
thalidomide was detrimental to embryonic development, and over 10,000 children 
were born with defects due to thalidomide exposure. Because of the thalidomide 
tragedy, new therapeutic agents must be screened in at least two different animal 
models, typically a rodent and a non-rodent model, before being approved for 
use [36-38]. 
 
Testing in large numbers of animals can be both time consuming and expensive. 
However, small animals, such as zebrafish and chicken embryos, limit the 
number of large mammalian animals required for initial screening, and allow for 
the testing of a large number of compounds [39-42]. Such assays allow a 
preliminary understanding of the toxicity and pharmacology and could elucidate 
molecular mechanisms underlying the drug action. Mammals, such as non-
human primates (NHPs) and rodents, are more representative of the effect on 
human development. However, in an age where the use of pregnant animals in 
research is becoming increasingly regulated, and the public perception of animal 
use, puts pressure on reducing the number of mammals used in research, the 
use of embryos from lower species to provide preliminary information is 
becoming increasingly useful. Consequently, the development of new, cost-
effective systems for the efficient and sensitive detection of hazardous agents is 
vital. The following sections describe the uses, benefits, and hindrances, of using 
zebrafish, chicken, mouse, rabbit and NHPs for the use of screening for anti-
angiogenic agents, and understanding the angiogenic process.  
 
-Zebrafish (Danio rerio) 
Unlike mammals, which can be costly to keep, zebrafish are relatively 
inexpensive. Embryos develop externally from the mothers, and develop rapidly, 
and the optical transparency of the tissues permits in vivo observation of 
angiogenesis and organ morphology. Vasculogenesis and angiogenesis in the 
zebrafish have been well characterized for the purpose of studying vascular 
physiology [40, 43-46] and for drug screening [41, 47-54]. Like other vertebrates, 
	 7	
the development of the zebrafish cardiovascular system begins with the 
differentiation of precursor cardiovascular cells from the lateral mesoderm. At 
approximately 12 hours post-fertilization (hpf), the cells of the mesoderm express 
SCL/Tal-1 and Flk1, beginning the differentiation of the cells to hemangioblasts. 
The original vessel in the vertebrate trunk (the dorsal aorta) forms by 
vasculogenesis. Subsequent intersegmental vessel (ISV) formation occurs by 
sprouting from the dorsal aorta at approximately 24 hpf. The sprouts migrate 
between the somites to anastomose and culminate in the formation of the dorsal 
longitudinal anastomic vessel. Blood vessels in the zebrafish are similar to those 
of other vertebrates; the vasculature is a single cell layer of endothelial cells, with 
smooth muscle cells, pericytes and fibroblasts supporting the structure [55]. Like 
other vertebrates, molecular regulation of vessel morphogenesis involves the 
VEGF ligands and their receptors [56], BMPs [57], and intrinsic cell-cell 
communication [58]. 
 
The zebrafish has been successfully utilized as a model system for screening 
compounds that alter angiogenesis for over 15 years [40, 51, 59]. The zebrafish 
can be exposed to the compounds early in development, then fixed and stained 
at a set time point. Changes in the vasculature can be quantified by assessing 
the number of forming intersomitic vessels, and by measuring the extent of their 
outgrowth. Anti-angiogenic agents may reduce the number, or length of 
outgrowth of these vessels.  Additionally, because angiogenesis is essential for 
organ development, the effects of compounds can be compared based on the 
observational outcome. Past studies have quantified eye growth, pectoral fin 
outgrowth and otic vesicle development as markers for anti-angiogenic action, as 
well as effects on spinal development (for example, curved or twisted spines) and 
a general restriction in the growth of the body size [5, 60]. While these 
measurements can be easily made in the laboratory by imaging each treated 
zebrafish, several studies have optimized this process for high throughput 
screening. Robotic systems can automatically position zebrafish, and composite 
images can be created by imaging layers of the translucent zebrafish embryo 
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[39]. The zebrafish embryo assay has major advantages; hundreds of 
compounds can be quickly screened in multiwell plates, zebrafish development is 
fast and allows for rapid output of results and the highly characteristic and 
hardwired vessel patterning means the assessment of effects is straightforward 
compared to higher animals [54, 60].  
 
One of the key advantages of the zebrafish embryo is the ability to image 
embryos in vivo and throughout development. Another key advantage of the 
zebrafish is the ability to generate tissue-specific transgenic lines, in particular 
one that allows visualization of the vasculature throughout development and 
effects of compounds upon the process [61]. The use of the transgenic fli1:EGFP 
zebrafish allows for the imaging of blood vessels and to observe the effects of 
drugs in living tissue (Figure 4A, B). fli1 is a well established endothelial cell 
marker, meaning transgene expression of the enhanced green fluorescent 
protein (EGFP) is tissue specific [61]. Development of the naïve vessels can be 
tracked and quantified, and the extent of outgrowth can be used as a reliable in 
vivo assessment of angiogenesis [50-52, 54, 62-67]. This can also be translated 
to high throughput screening, for example, by reading fluorescent intensity in the 
living zebrafish [68].  
 
The translational ability of the efficacy and toxicity of anti-angiogenic drugs 
exposed to fli1:EGFP zebrafish has been established. By screening a range of 
well characterized angiogenesis inhibitors, Chimote et al [62] demonstrated that 
the zebrafish assay could differentiate anti-angiogenic compounds acting by 
VEGFR inhibition (such as sunitinib), and those acting by non-selective 
cytotoxicity, like TNP-470, a Met-AP2 inhibitor (Figure 3). Similar results have 
been seen regarding vascular development in anti-angiogenic compound treated 
zebrafish embryos [54]. The anti-angiogenic monoclonal antibodies (such as 
bevacizumab) did not reduce vessel outgrowth (likely due to lack of humanized 
antibody binding to the zebrafish ortholog) demonstrating the assays ability to 
separate drugs by mechanism. The results correlated well with other in vitro and 
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in vivo assays [54, 62]. Confirmation of the activity of compounds in the zebrafish 
assay, has streamlined the preclinical drug discovery process [50-52]. Due to 
their size, the zebrafish is easily converted to high-throughput screening assays 
[39]. For researchers interested in cancer development and cancer angiogenesis, 
the adult zebrafish is amenable to cancer cell grafts. Similar in vivo imaging 
assays can be used to assess the effect of anti-angiogenic therapies on the 
tumor vasculature [69]. 
 
Zebrafish embryos are also useful for deciphering molecular mechanisms of 
action, and to elucidate causes of teratogenesis. Thalidomide has been shown to 
mediate anti-angiogenic teratogenic actions by depleting VEGF receptors [70] 
leading to reduced filopodial extension and tube formation [64]. Thalidomide has 
been shown to reduce pectoral fin outgrowth in zebrafish [52, 71]. Zebrafish with 
non-functional cereblon do not produce the fin defects when exposed to 
thalidomide, suggesting that thalidomide-induced teratogenicity may occur by 
binding to the cereblon complex [71]. Since this finding, several clinical reports 
have shown a correlation between cereblon expression and the response to 
thalidomide, and its analogs lenalidomide and pomalidomide in the adult 
condition, multiple myeloma [72-75].  
 
-Chicken 
The chicken embryo is a well-established model in experimental embryology due 
to its accessibility to micromanipulation techniques during organogenesis stages 
[76-79]. The chicken embryo is increasingly also being used for drug screening 
and understanding how anti-angiogenic drugs act [50-52, 54, 64, 80-83].  
 
By using standard toxicology testing end points, including gross anatomy 
development, reductions in size/mass of cartilage elements and eye size, the 
chicken embryo can be used to rapidly assess the teratogenicity of new 
compounds. For example, the chicken embryo has been used to assess the 
teratogenic actions of the anti-epileptic drug, Valproic acid [84, 85]. Valproic acid 
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has been used in the treatment of epilepsy, psychiatric disorders, migraines, and 
in preventing seizures [86]. Recent research has also implicated its efficacy in 
the treatment of AIDS and cancer (phase 2 clinical trials), due to the drug’s ability 
to inhibit histone deacetylase [86]. Exposure of the human embryo to valproic 
acid can lead to harm to the developing embryo and is commonly referred to as 
fetal valproate syndrome, where damage includes spina bifida, and cranio-facial 
defects [87, 88]. In the developing chicken embryo, valproic acid has been shown 
to be anti-angiogenic and teratogenic [84], producing a pattern of defects similar 
to those in humans including neural and cardiac defects [89] and limb reduction 
defects [84]. Several mechanisms have been proposed to explain the teratogenic 
effect of valproic acid including reduced embryonic folate metabolism [90], 
hypoxia induced vascular insults [91] and alterations in retinoid metabolism [92, 
93].  
 
The chicken embryo has also been utilized to study thalidomide-induced defects 
since the 1960s [94, 95]. The limb defects produced in chickens exposed to 
thalidomide during development do share some similarities to those seen in 
human thalidomide embryopathy cases [64, 94-98]. Indeed, thalidomide 
exposure can result in damage to the axial artery supplying the forming forelimbs 
with blood [96]. More recently studies have shown thalidomide can induce cell 
death [97] and changes to the vessel networks in the chorioallantoic membrane 
(CAM), that supplies nutrients from the yolk to the embryo [99] and CPS49, an 
anti-angiogenic analog of thalidomide, can cause a time-sensitive range of limb 
reduction anomalies [64, 98]. Further studies have shown that the chicken 
embryo can also be used to identify anti-angiogenic, teratogenic thalidomide 
analogs [50-52] and teratogenic risk of anti-angiogenic compounds [54]. The 
molecular mechanisms the drug influences to cause defects has also been 
explored using the chicken embryo, showing that many important signals 
involved in limb outgrowth and patterning, including Fgf8, Fgf10, Shh, BMP and 
Wnt signaling, is altered in limb buds exposed to thalidomide [97, 100] and to 
CPS49 [64]. 
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In addition to utilizing the embryo itself, the surrounding yolk sac membrane 
(YSM) and the chorioallantoic membrane (CAM) can be used to demonstrate a 
compounds anti-angiogenic activity or potential [54, 82, 83, 101, 102]. The YSM 
and the CAM are extraembryonic membranes formed during chicken embryo 
development. The YSM develops early around HH St10 and is the first site where 
blood vessels form from angioblasts (i.e. vasculogenesis) which then spread all 
over the yolk (through angiogenesis) and supplies nutrients to the embryo. The 
CAM forms from day 4 and is a fusion of the allantois and the chorionic 
membrane. The CAM is attached to the embryo, and exponentially increases in 
size as the embryo develops. Its function is to remove waste products. In these 
bioassays, a sponge, bead, or gel soaked in the compound of interest is placed 
upon the YSM or CAM, and left for a designated period of time. At the end point, 
the vessels can be quantified using imaging or colourmetric analysis [83]. The 
YSM and CAM assay is therefore useful for rapid investigation of compounds, 
but the number of eggs required to perform the assay may limit its use. In 
summary, the chicken embryo model can be used to evaluate angiogenesis, 
teratogenic risk, and the molecular effects of drugs (Figure 4C-D).  
 
 
-Rodents 
The use of mice as experimental models is well documented. Around 95% of our 
DNA is shared with that of a mouse [103], and most of the shared diseases are 
caused by the same genetic changes [104]. During mouse embryonic 
development, angioblast cells generated in blood islands at E7.0 integrate in the 
embryonic mesoderm post-gastrulation to develop the vascular plexus at around 
E8.5 [105-107]. The connection of the embryonic vasculature with the yolk sac 
vasculature is thought to take place between E8.25-E9.0 [108]. Through 
angiogenesis, extensive remodelling and recruitment of the pericytes and smooth 
muscle to the vascular wall, the primitive network is developed and matured 
[105]. Crucial signalling factors during blood vessel development include 
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VEGF,the previously discussed signaling factor essential for angiogenesis [109-
111]. Recruitment of pericytes and smooth muscle to form mature blood vessels 
is regulated by the angiopoietin/Tie2 system. In response to angiopoietin/Tie2 
interaction, endothelial cells release platelet-derived growth factor (PDGF) to 
attract local mesenchymal cells, which then differentiate in to pericytes and 
smooth muscle cells [112, 113]. 
 
Angiogenesis in mice is often studied in relation to cancer, since angiogenesis is 
required for tumour growth [114]. Folkman, Haudenschild and Zetter [115] 
isolated the first angiogenic and anti-angiogenic factors from animal tumours 
[115]. These early studies lay the foundations for development of anti-angiogenic 
drugs for the treatment of cancer. The most common procedure used to analyse 
angiogenesis in tumour growth in adult mice is the transplantation of a tumour 
cell line in to immune deficient mice [116]. Anti-angiogenic drugs, for example 
soluble receptors or neutralising antibodies, have been developed for cancer 
treatment utilising mouse tumour models. 
 
Adult mouse models have also been utilised to study conditions such as 
ischemia, where restricted blood supply to a particular area of the body can 
cause tissue damage. A mouse model of hindlimb ischemia was made by ligation 
and excision of the femoral artery, which demonstrated that neovascularisation, 
characterised by increased capillary density and endothelial cell proliferation, 
was dependent on up-regulation of VEGF expression. VEGF expression was 
increased up to 14 days after ischemia was induced compared to non-operated 
limbs. Indeed, neutralising VEGF protein prevented neovascularisation in the 
ischemic limb, therefore demonstrating VEGF is a key regulator of angiogenesis 
[117]. Mice and rat models of myocardial infarction are also used to evaluate 
drug treatments, since the neovascularisation involved in wound healing after a 
myocardial infarction is very efficient [118]. 
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An advantage of the mouse is the ability to make transgenic tissue reporter lines. 
Though embryo development can not be followed live and in vivo like the 
zebrafish and chicken, the ability to make tissue specific reporter lines also 
allows tissue specific knockdown to test gene function. For example, 
angiogenesis has been visualized during embryonic development through 
utilising mouse strains expressing β-galactosidase gene in endothelial cells [119-
122] Two receptor tyrosine kinase (RTK) families are nearly exclusively 
expressed by endothelial cells: vascular endothelial growth factor receptors 
(VEGFR1-3) and Tie receptors (Tie1-2). VEGFR-1 acts primarily to restrict 
angiogenesis, and VEGFR-2 and VEGFR-3 act to stimulate angiogenesis of 
vascular and lymphatic endothelial cells, respectively [123]. The platelet-derived 
growth factor (PDGF) and Eph receptor tyrosine kinases are also important 
during angiogenesis, and are required for stabilization of vascular walls and in 
characterization of arterial versus venous vessels, respectively [124, 125]. Fong 
et al. [119] used targeted mutations at the Fms-related tyrosine kinase 1 (Flt-1) 
locus (flt-llcz), encoding the VEGFR-1 protein, to determine that Flt-1 is necessary 
for organisation of vasculature during embryogenesis [119]. Tie1-2 receptors and 
angiopoietin ligands exhibit context dependent roles in endothelial cell survival 
and in remodeling of the vessel networks [126]. Puri et al. [120] generated Tie-
1lcz(-/-) mice to show that receptor tyrosine kinase TIE-1 is essential to maintain 
integrity of vascular endothelial cells [120]. 
 
Mice are fundamental for angiogenesis research, but unfortunately mice can 
respond differently upon exposure to anti-angiogenic compounds compared to 
humans [127]. Perhaps the best known example is thalidomide where mice and 
rats appear to be insensitive or less sensitive to thalidomide with several studies 
reporting no skeletal abnormalities [128-130] though in some strains of mice 
thalidomide-induced damage has been observed [131, 132]. Interestingly 
thalidomide exposure in late pregnancy in rats has been shown to cause brain 
damage in areas associated with autism in humans, and has been linked to 
blood vessel loss [133]. Explanations for the apparent resistance of rodents to 
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thalidomide include that rodents may produce more efficient antioxidants against 
free radicals, thalidomide has a shorter half-life in rodents and does not appear to 
induce apoptosis as it does in humans [134-136]. Another factor may be 
differences in metabolism and clearance rates of the drug [36, 137-139]. Indeed, 
a recent paper using a transgenic mouse line where CYP3 metabolic enzymes 
were missing from the placenta resulted in mouse embryos with some 
thalidomide-induced defects [140]. In terms of anti-cancer drugs to treat tumours 
or tumour grafts in the animal, rodents do show strain-differences in their ability 
to respond to these compounds. This may be a result of implantation sites of 
tumour cells (frequently xenografts are subcutaneous) [127, 141] and the speed 
of cancer growth since tumour developmental processes can take weeks in mice 
and years in humans [142]. Crucially, there is also wide genetic variation 
between humans who develop cancers, which is not reflected when using 
experimental mouse models bred from strains of identical backgrounds [127]. 
While incredibly useful, developing rodent embryos are not as readily 
manipulated or as accessible as zebrafish or chicken embryos, so consequently 
in vitro assays are used to test the effect of anti-angiogenic factors. The 
maintenance is more costly, and in vivo imaging becomes much more invasive 
than with smaller animal models. 
 
 
-Rabbits 
Rabbits are one of the most commonly used non-rodent species in toxicological 
testing, after mice and rats [143]. They are relatively easy to maintain and breed 
and have short gestation periods. However, development of the embryo and 
effects of drugs in vivo are difficult to observe as embryonic development occurs 
in the uterus. Developmental toxicity studies have been performed on rabbit 
embryos to screen agents such as drugs (eg: thalidomide) and industrial 
compounds [144, 145]. In addition whole mount embryo cultures can be useful in 
order to analyse the effect of compounds upon embryo development [144, 146]. 
A retrospective study comparing rat and rabbit in vivo studies, showed similar 
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sensitivity between rats and rabbits in drug screens, and perhaps explains why 
rats are more widely used to test drug action [145]. In contrast, Theunissen [147]  
demonstrated some species differences between rat and rabbit in the 
development of embryo-fetal developmental toxicity, for example fetal 
malformations were more commonly seen in the rat, whereas embryo-fetal death 
and embryo resorption was more prominent in the rabbit [147]. Taken altogether, 
these studies show that selective toxicity and species differences in testing of 
developmental toxicity is fairly common.The use of both rodent and non-rodent 
species is suggested as more beneficial in detecting developmental toxicants 
compared to the use of one species alone [147, 148]. 
 
Many of the studies in vasculogenesis and angiogenesis performed in rabbit are 
carried out in adult animals. Rabbit corneal pocket assay is used to test the 
antiangiogenic capacity of determined compounds. One important example of the 
use of this technique was the landmark paper by D’Amato and colleagues [149]. 
Within this study, the authors promoted angiogenic outgrowth in the rabbit eye 
using FGF pellets, and subsequently observed which agents were able to reduce 
or inhibit the angiogenic outgrowth. Using this method, the authors became the 
first group to demonstrate thalidomide`s anti-angiogenic properties. They 
hypothesized upon the use of thalidomide as an anti-angiogenic therapeutic, and 
proposed that the anti-angiogenic actions may be responsible for the teratogenic 
effects [149].  
 
 
-Non-human primates 
Non-human primates (NHPs) are more similar to humans than the other 
mammalian models, and so likely provide a more relevant understanding of 
angiogenesis and drug action [150]. Indeed, studies have been performed to 
investigate the role of vascularisation and angiogenesis during early pregnancy 
and development, and the molecules that control these processes. For example, 
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in baboons, oestrogen controls the expression of VEGF in placental 
vascularization [151].  
 
NHPs particularly the common marmoset (Callithrix jacchus) and cynomolgus 
monkey (Macaca fascicularis) have been used to assess the teratogenic 
potential of drugs including those with anti-angiogenic and anti-cancer properties 
[152, 153]. One of the more widely studied drugs in NHPs is thalidomide.  
Cynomolgus monkey’s following thalidomide exposure exhibit forelimb and 
hindlimb defects, as well as craniofacial defects, tail and genital organ defects 
[154]. In addition, the defects caused by thalidomide can vary widely among the 
offspring from severe, where all limbs are effected to mild where just the tail 
appears abnormal [154-156]. Similarly, a study analysing the potential 
teratogenic effects of a potent thalidomide analog EM-12 (2-(2,6-dioxopiperidine-
3-yl)-phthalimidine) in the common marmoset resulted in embryos presenting a 
range of defects similar to humans, among them forelimb and hindlimb defects 
(amelia, phocomelia), defects on mandibular, palate, ribs and tail [155, 156]. 
Further analysis suggested cell adhesion molecule changes occur following EM-
12 exposure and have been proposed to be a potential target of thalidomide 
embryopathy [157, 158]. Furthermore, in Cynomolgus monkey fetuses following 
exposure to thalidomide, thousands of gene changes were identified, many of the 
genes related to actin cytoskeletal remodelling and genes involved in vasculature 
development [154]. A down-regulation of vascular pathways may effect vascular 
cell proliferation and recruitment in developing limbs and lend support to previous 
proposals suggesting limb defects are secondary to disruption in blood vessel 
development [37, 98, 136, 154].  
 
Thalidomide is also a potent anti-inflammatory agent [35, 37]. A high level of 
crosstalk is observed between the vascular and inflammatory pathways. Yet 
although down-regulation of inflammatory genes may reflect a protective 
response to thalidomide, down-regulation of genes in both pathways by the drug 
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suggests the effects of thalidomide are likely seen across a range of regulatory 
processes [37, 154, 159].  
When and how drugs cause effects in the forming NHP embryo is unclear. As the 
embryo develops in utero, studies to follow the effects in real time are very 
difficult particularly in comparison to zebrafish and chicken embryos, where 
general effects on angiogenesis and embryonic development can be seen and 
followed with relative ease. Once the effects of drugs/compounds in smaller 
animals are known, later studies in NHPs can shed light on other effects or be 
used to check agents safety in a more human relevant model. 
 
Summary 
The formation of a functional blood supply by vasculogenesis and angiogenesis 
is a required precursor to the development of the cardiovascular system during 
embryogenesis. Few data are available on the safety of anti-angiogenic drugs 
when given during pregnancy; although factors such as mechanism, dose, 
bioavailability, and developmental stage must be considered, accumulating 
evidence suggests that anti-angiogenic drugs as a class may be teratogenic [54]. 
Anti-angiogenic compounds are contraindicated during pregnancy due to the 
disruption of the delicate embryonic vasculature.  Most anti-angiogenic 
compounds carry a FDA category C (for example bevacizumab) or D (for 
example sunitinib) warning, indicating that adverse events are seen when drugs 
are taken during fetal development but studies are limited. A demand still exists 
for thorough and reliable methods for the detection of teratogens, particularly 
identification of anti-angiogenic drugs. A well-integrated understanding of the 
intricate development of the vasculature and new methods of drug screening 
may offer opportunities for therapeutic intervention and identifications of 
mechanisms of teratogenicity. Small animal models are incredibly useful in the 
early stages of preclinical drug development. However, reproductive toxicology 
studies are usually conducted late in the drug development process, and 
unexpected results are costly. Animal studies do not obviate concerns related to 
teratogens that are uniquely harmful to humans and thus extrapolation of data 
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obtained from non-mammalian models must be done with caution. Nonetheless, 
the ability to accurately predict a drugs action reduces the number of large 
animals required, and increases the safety profile of new drugs. Although we 
discuss in vivo developmental models, which encapsulate more of the angiogenic 
process than an in vitro culture system, knowledge gained from in vitro 
experiments are incredibly useful, and should not be negated. At present, 
combining in vitro and in vivo results gives the most accurate representation of 
fetal drug toxicity. Adapting these models to mimic human development will 
enable the prediction of drug targets, and thus the effect on embryogenesis, in 
the preclinical phase of drug development. Ultimately, these will give the best 
indication of a given agents potential teratogenic properties, allowing physicians 
and patients to make a well-informed decision on their treatment course. 
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Figure Legends 
 
Figure 1: Vasculogenesis and angiogenesis. Endothelial cell precursors 
(angioblasts) are derived from mesodermal stem cells. Angioblasts are promoted 
by vascular endothelial growth factor (VEGF) and its co-receptor neuropilin-1, to 
migrate, differentiate, and assemble into endothelial cords. The primitive vascular 
plexus forms from merging of the endothelial cords with the endocardial tubes 
(vasculogenesis). The expansion and remodeling (angiogenesis) leads to 
stabilized vessels in a vascular network. This is mediated by VEGF, as well as 
other factors (such as Sonic hedgehog and Notch signaling). Vessels are 
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stabilized by mural cells, a process mediated by platelet derived growth factor B 
(PDGF) acting upon its receptor (PDGFR). Adapted from [160] and [161]. 
 
Figure 2: Molecular mechanisms controlling angiogenesis. 
 
Figure 3: Angiogenesis and angiogenesis inhibitors. (A) Angiogenesis is 
promoted by tumour cells and neighbouring stromal cells. Endothelial cells are 
activated by pro-angiogenic factors released by these cells and they begin to 
migrate. They then proliferate and stabilize, while the angiogenic factors continue 
to promote the process in a feedback loop. Vessels penetrate the environment of 
the cancerous cells allowing the tumour to grow. (B) At the molecular level, 
angiogenesis inhibitors reduce the inappropriate blood vessel growth by targeting 
VEGF receptors directly (sunitinib, sorafenib, axitinib), a downstream molecular 
target (sorafenib, vandetanib, pazopanib) or by acting within the tumour cells 
themselves to inhibit the production of pro-angiogenic factors such as VEGF 
(everolimus) [54, 162]. 
Figure 4: Angiogenesis in the zebrafish and developing chicken embryo as 
a tool for assessing drug action. (A) Normal vascular development at 24 hours 
post fertilization and (B) reduced vascular development in an anti-angiogenic 
drug (sunitinib) treated transgenic fli1:EGFP embryo. Angiogenesis is quantified 
by measuring intersomitic vessel (ISV) number and outgrowth. Selected ISVs are 
indicated by white arrow heads. The anterior (head) and posterior (tail) regions 
are indicated. The yolk sac (YS) is indicated.  (C) A chicken embryo with normal 
eye (e), limb bud (l) and spinal (s) development. (D) Chicken embryo following 
treatment for 24 hours with an anti-angiogenic drug (sunitinib). Note hemorrhagic 
tissues (black asterisk) and bent spine of the embryo (black arrowhead). The 
chorioallantoic membrane (CAM) and yolk sac membrane (YSM) are indicated. 
Images are from previously unpublished work of Beedie, Figg and Vargesson 
from a published study [54]. 
 
